Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies

Published on January 7, 2022

Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.

Continue reading on website
Other news

Alaska Air (ALK) Arm Trims January Schedule Amid Omicron Woes

January 7, 2022
Alaska Air Group (ALK) unit Alaska Airlines plans to cut January flights by roughly 10% due to a spike in coronavirus cases among its staff.

The Power of Price Charts: Trust Your Eyes, Not Your Ears

January 7, 2022
The Power of Price Charts: Trust Your Eyes, Not Your Ears